菜单

Perspectives

WuXi Biologics accelerates development, manufacturing with robust model, platforms
Mar. 11, 2026
WuXi Biologics accelerates development, manufacturing with robust model, platforms

Dr. Chris Chen, CEO of WuXi Biologics, recently had an exclusive interview with Pharma Manufacturing and shared the company’s high-quality, reliable, and efficient biologics R&D and manufacturing solutions, as well as his insights into the industry.

 

Over the past decade, the Contract Research, Development and Manufacturing Organization (CRDMO) sector has grown rapidly. An increasing number of pharmaceutical innovators are choosing to partner with CRDMOs that offer flexible, high-efficiency solutions to advance increasingly complex novel therapies quickly and reliably.

 

As a world-leading CRDMO, WuXi Biologics enables biopharmaceutical companies to stay competitive in a fast-evolving industry. At the J.P. Morgan Healthcare Conference earlier this year, WuXi Biologics announced that its total integrated project pipeline had grown strongly to 945 projects. Among these, its bispecific/multispecific antibody business has become the company’s fastest-growing engine, with a pipeline of 196 projects.

 

In this exclusive interview, Dr. Chen elaborated on WuXi Biologics’ development model and highlighted the company’s industry-leading technology platforms — key enablers for the high-quality development and manufacturing of biologics.

 

Click Read More to view the full original English interview article.

WuXi Biologics accelerates development, manufacturing with robust model, platforms | Pharma Manufacturing